Pfizer Operating Income 2010-2023 | PFE
Pfizer annual/quarterly operating income history and growth rate from 2010 to 2023. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
- Pfizer operating income for the quarter ending December 31, 2023 was $-4.609B, a 205.2% decline year-over-year.
- Pfizer operating income for the twelve months ending December 31, 2023 was $222M, a 99.36% decline year-over-year.
- Pfizer annual operating income for 2023 was $0.222B, a 99.36% decline from 2022.
- Pfizer annual operating income for 2022 was $34.944B, a 79.82% increase from 2021.
- Pfizer annual operating income for 2021 was $19.433B, a 135.55% increase from 2020.
Pfizer Annual Operating Income
(Millions of US $) |
| 2023 |
$222 |
| 2022 |
$34,944 |
| 2021 |
$19,433 |
| 2020 |
$8,250 |
| 2019 |
$6,710 |
| 2018 |
$5,672 |
| 2017 |
$13,722 |
| 2016 |
$12,145 |
| 2015 |
$11,824 |
| 2014 |
$13,249 |
| 2013 |
$15,184 |
| 2012 |
$15,264 |
| 2011 |
$13,967 |
| 2010 |
$13,412 |
| 2009 |
$10,959 |
Pfizer Quarterly Operating Income
(Millions of US $) |
| 2023-12-31 |
$-4,609 |
| 2023-09-30 |
$-3,430 |
| 2023-06-30 |
$1,921 |
| 2023-03-31 |
$6,340 |
| 2022-12-31 |
$4,381 |
| 2022-09-30 |
$8,943 |
| 2022-06-30 |
$12,219 |
| 2022-03-31 |
$9,401 |
| 2021-12-31 |
$2,991 |
| 2021-09-30 |
$6,147 |
| 2021-06-30 |
$5,606 |
| 2021-03-31 |
$4,689 |
| 2020-12-31 |
$703 |
| 2020-09-30 |
$2,448 |
| 2020-06-30 |
$2,072 |
| 2020-03-31 |
$3,027 |
| 2019-12-31 |
$-4,928 |
| 2019-09-30 |
$2,958 |
| 2019-06-30 |
$4,266 |
| 2019-03-31 |
$4,414 |
| 2018-12-31 |
$-6,017 |
| 2018-09-30 |
$3,764 |
| 2018-06-30 |
$3,976 |
| 2018-03-31 |
$3,949 |
| 2017-12-31 |
$2,307 |
| 2017-09-30 |
$3,664 |
| 2017-06-30 |
$3,741 |
| 2017-03-31 |
$4,010 |
| 2016-12-31 |
$1,756 |
| 2016-09-30 |
$3,021 |
| 2016-06-30 |
$3,477 |
| 2016-03-31 |
$3,891 |
| 2015-12-31 |
$1,834 |
| 2015-09-30 |
$3,358 |
| 2015-06-30 |
$3,595 |
| 2015-03-31 |
$3,037 |
| 2014-12-31 |
$2,147 |
| 2014-09-30 |
$3,682 |
| 2014-06-30 |
$3,950 |
| 2014-03-31 |
$3,470 |
| 2013-12-31 |
$3,043 |
| 2013-09-30 |
$3,984 |
| 2013-06-30 |
$4,287 |
| 2013-03-31 |
$3,870 |
| 2012-12-31 |
$2,560 |
| 2012-09-30 |
$3,743 |
| 2012-06-30 |
$4,868 |
| 2012-03-31 |
$4,093 |
| 2011-12-31 |
$1,913 |
| 2011-09-30 |
$4,088 |
| 2011-06-30 |
$4,021 |
| 2011-03-31 |
$3,945 |
| 2010-12-31 |
$1,887 |
| 2010-09-30 |
$3,763 |
| 2010-06-30 |
$4,201 |
| 2010-03-31 |
$3,561 |
| 2009-12-31 |
$-39 |
| 2009-09-30 |
$4,131 |
| 2009-06-30 |
$3,121 |
| 2009-03-31 |
$3,746 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$143.942B |
$58.496B |
|
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
|
